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Background: Few studies have been conducted in Pakistan to determine the efficacy of chloroquine and
sulphadoxine-pyrimethamine (SP), which remain in use as treatment for Plasmodium vivax and in combination with
artesunate to treat Plasmodium falciparum, respectively. In this study, samples from several sites across Pakistan
were characterized to determine prevalence of molecular resistance markers in the P. falciparum chloroquine
resistance transporter (pfcrt), multidrug resistance (pfmdr1), dihydrofolate reductase (pfdhfr) and dihydropteroate
synthase (pfdhps) genes and the origin of chloroquine-resistant P. falciparum parasites.
Methods: Microscopy-confirmed malaria parasite-positive blood samples from 801 patients across the country were
collected in 2011. Of these, 171 infections were identified by polymerase chain reaction (PCR) as P. falciparum and
analysed by pyrosequencing for mutations conferring chloroquine resistance (pfcrt codons 72–76), multidrug
resistance (pfmdr1 N86Y, Y184F, S1034C, N1042D and D1246Y), pyrimethamine resistance (pfdhfr, C50R, N51I, C59R,
S108N and I164L) and sulphadoxine resistance (pfdhps, S436A, A437G, K540E, A581G and A613T/S). pfmdr1 gene
copy number variation was determined by real-time PCR, and microsatellites flanking the pfcrt locus were typed to
determine the origin of the chloroquine-resistant haplotype.
Results: The pfcrt K76T mutation was found in all samples as part of the S72/V73/M74/N75/T76 (SVMNT) haplotype.
Microsatellites flanking pfcrt showed high similarity to the signature found in India and Papua New Guinea. pfmdr1
N86Y was found in 20% of samples and all samples harboured a single copy of the pfmdr1 gene. The pfdhfr double
mutation C59R + S108N was present in 87% of samples while the pfdhfr triple mutant (N51I + C59R + S108N) was
not detected. Pfdhps A437G was found in 60% of samples. Pure pfdhps K540E was rare, at 4%, but mixed genotype
540 K/E was found in 77% of samples. Similarly, pure pfdhps A581G was found in 4% of the isolates while mixed
581A/G was found in 39% of samples.
Conclusions: These results suggest an emerging problem with multidrug resistant P. falciparum in Pakistan. The
chloroquine resistance genotype has reached complete fixation in the population, with a microsatellite pattern
indicative of a selective sweep. Moreover, the prevalence of mutations in both pfdhfr and pfdhps, albeit without the
presence of the pfdhfr triple mutant, indicates that continued monitoring is warranted to assess whether SP
remains efficacious as a partner drug for artesunate for the treatment of P. falciparum.
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In Pakistan, an estimated 500,000 episodes of malaria infec-
tion occur annually [1]. Although the majority of these
cases is attributed to Plasmodium vivax, studies indicate
that Plasmodium falciparum in Pakistan has been on the
rise over the past few decades [2]. The proportion of mal-
aria infections attributed to P. falciparum rose from 34 to
54% between 1987 and 1990 in north-west Pakistan [3],
and the frequency of P. falciparum among microscopy-
positive cases rose from 45% in 1995 to 68% in 2006 in the
provinces of Balochistan and Sindh [4,5]. In 2010, out of a
total of 240,591 reported malaria cases in Pakistan, 73,857
(31%) were P. falciparum [6].
The first-line treatment of uncomplicated malaria of
undetermined species in Pakistan is chloroquine. Chloroquine-
resistant P. falciparum was first reported in Pakistan in
1984 [3] and subsequent in vivo studies have confirmed
that chloroquine is not an efficacious treatment for
P. falciparum in Central Asia. A survey conducted in
western Pakistan in Afghan settlements during 1994–1995
reported in vivo chloroquine resistance ranging from 18
to 62% [7]. Both standard and extended-dose courses of
chloroquine resulted in high levels of treatment failure in
clinical studies conducted in Afghani refugees in Pakistan
[8]. Other clinical studies conducted in refugee communi-
ties throughout the country indicated that chloroquine re-
sistance increased as much as 15% in exposed populations
in a single year, rising five- to six-fold between 1982 and
1992 [2].
In response to the declining efficacy of chloroquine,
the World Health Organization (WHO) recommended
artesunate plus sulphadoxine-pyrimethamine (AS + SP)
as the first-line choice of treatment for uncomplicated P.
falciparum malaria in Pakistan [9]. However, a 56%
treatment failure rate with SP monotherapy was
reported in Balochistan province in a study conducted
between 2001 and 2005 [10], indicating that SP may be
compromised as an effective partner drug.
Molecular surveillance of drug resistance has been
used extensively to monitor sensitivity to chloroquine
and SP. A point mutation causing an amino acid change
from K to T at codon 76 of the P. falciparum chloro-
quine resistance transporter gene (pfcrt) confers resist-
ance to chloroquine in vitro [11,12] and is strongly
associated with treatment failure in vivo [13]. The role
of these mutations in chloroquine resistance has also
been confirmed by transfection studies [11]. A small
number of independent pfcrt resistant lineages has been
found: two in South America, one in Papua New Guinea
[14] which has also been found in Asia [15,16], one ob-
served in the Philippines, and one in Southeast Asia
which spread to Africa [14,17].
Mutations in the dihydropteroate synthase (pfdhps) and
dihydrofolate reductase (pfdhfr) genes of P. falciparumconfer resistance to SP. Point mutations at positions N51I,
C59R, S108N and I164L in pfdhfr are associated with pyri-
methamine resistance in vitro [18-20] and treatment fail-
ure in vivo [21-23]. Resistance to sulfas is conferred by
mutations at codons A437G, K540E, A581G and A613T/S
of the pfdhps gene, confirmed by in vitro [24-28] and
in vivo [22-24] studies. Resistance to SP occurs in a step-
wise fashion, with an increasing number of mutations in
pfdhfr and pfdhps contributing to an increased risk of
treatment failure [29]. Infections carrying the pfdhfr triple
mutant (S108N+N51I + C59R) are significantly more
likely to fail SP treatment than infections with fewer pfdhfr
mutations [30], and the pfdhfr/pfdhps quintuple mutant
(pfdhfr triple mutant S108N +N51I + C59R plus the pfdhps
double mutant A437G + K540E) is highly predictive of
clinical failure in Africa [23,29,31].
Elevated copy number of the pfmdr1 gene is associated
with susceptibility of P. falciparum to artemisinin, mef-
loquine, and lumefantrine [32-34], and has been used as
a surveillance tool for artesunate-mefloquine resistance
in Southeast Asia [33,35]. Mutations in the pfmdr1 gene
leading to the substitution of amino acids including
N86Y, Y184F, S1034C, N1042D, and D1246Y also modulate
in vitro susceptibility to a number of drugs [36], although
their relevance in conferring clinical resistance remains
uncertain.
In Pakistan, previous molecular surveys of drug resist-
ance have focused on one or two sites in a small number
of geographic regions. In these surveys, the most recent
of which was conducted in 2007, high levels of pfcrt 76T
have been reported [1,15,37], and multiple mutations in
the pfdhfr and pfdhps genes have been found [1,37,38].
In this study, the prevalence of molecular markers of
anti-malarial resistance was investigated in a compre-
hensive survey over 14 sites in four provinces of Pakistan
and in the capital city of Islamabad. Collected in 2011,
these samples provide information on the current distri-
bution of drug-resistant genotypes in the pfcrt, pfmdr1,
pfdhfr and pfdhps genes five years after the implementa-
tion of artesunate + SP as the first-line treatment for un-
complicated P. falciparum.
Methods
Study sites and ethics
Government and private hospitals in 25 cities from four
provinces with the highest burden of malaria representing
all four provinces (Khyber Pakhtunkhwa province, Sindh
province, Balochistan province and Punjab province) and
a hospital in the capital city, Islamabad, were invited to
participate in the molecular survey in 2011. Although the
Federally Administered Tribal Areas have among the
highest burdens of malaria in the country, they were
excluded from this study because political instability
and violence [39] make it difficult to establish sample
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tals in 14 cities shared samples and were included in this
study (Figure 1). Symptomatic patients of all age groups
were enrolled and 3 mL of venous blood was drawn from
each patient. Consent was obtained from patients or from
children’s parents or guardians. Information on patient
age and gender was also collected. The study was ap-
proved by the institutional review board of Quaid-i-Azam
University, Islamabad, Pakistan.
Microscopy and sample collection
Thick and thin blood films of patients with suspected
malaria were stained with 10% Giemsa solution and ex-
amined at 1,000 ×magnification under oil immersion by
a laboratory technician or technologist trained in malaria
diagnosis according to WHO guidelines [40]. Approxi-
mately 50 μl of each blood sample from 801 malaria
microscopy-positive and 30 microscopy-negative sam-
ples was applied to Whatman 3MM filter paper. Filter
papers were air-dried overnight and stored at room
temperature in individual plastic bags with desiccant.
DNA extraction and speciation
Molecular analysis was conducted at the Howard
Hughes Medical Institute/University of Maryland SchoolFigure 1 2011 collection sites with malaria-positive isolates: 14 citiesof Medicine in Baltimore, MD, USA. DNA was extracted
from the blood-impregnated filter papers using the
QIAmp 96 DNA kit (Qiagen, Valencia, CA, USA). Plas-
modium species (P. vivax and P. falciparum) were con-
firmed by nested PCR amplification of the small subunit
ribosomal ribonucleic acid (ssrRNA) genes by using the
primers and thermal cycler conditions as previously de-
scribed [41]. PCR products were visualized by 2–2.5%
agarose gel electrophoresis using the Bio-Rad gel doc
system. Extracted DNA was stored at −20°C for further
analysis.Pyrosequencing of pfdhfr, pfdhps, pfcrt, and pfmdr1
codons
PCR for pyrosequencing of pfdhfr codons C50R, N51I,
C59R, S108N and I164L and pfdhps codons S436A,
A437G, K540E, A581G and A613T/S was conducted
using previously described cycling conditions [42] with a
few modifications. Nested PCR reactions were prepared
in 25 μl PCR reaction volume, contained 1 μl DNA tem-
plate, 1× PCR buffer (Qiagen, Valencia, CA, USA),
0.2 mM dNTPs (Invitrogen) and 0.05 units HotStar Taq
DNA polymerase (Qiagen, Valencia, CA, USA). The sub-
stitution of HotStar Taq required an initial incubation
step of at 95°C for 15 min for all PCR reactions. PCRin four provinces and the capital of Pakistan.
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(Bio-Rad, Hercules, CA). PCR primers and cycling con-
ditions for pyrosequencing of pfcrt codons 72–76 and
pfmdr1 codons N86Y, Y184F, S1034C, N1042D and
D1246Y are described on the investigator’s website [43].
Pyrosequencing for all genes was performed using
PyroMark® Q96 MD pyrosequencer, using the protocol
previously described [42]. Between 2 and 7 μl of second-
ary PCR product or sequence-specific amplified positive
control DNA provided by Malaria Research Reagent Re-
source (MR4) (Manassas, Virginia, USA) was added to
each pyrosequencing reaction, depending on the on the
PCR product yield. Single nucleotide polymorphisms
(SNPs) were called using PyroMark® Q96 MD
pyrosequencing software version 1.2 (Qiagen) in allele
quantification mode (AQ) for all SNPs except for pfcrt
72–76 and pfmdr1 N86Y, which were analysed in se-
quence analysis mode (SQA). Single peak signals of at
least 30 RLU (relative luminescence units) were consid-
ered suitable for allele quantification. Pyrosequencing
was repeated with an adjusted amount of PCR product
for samples failing to produce a SNP call because of too
much DNA (saturating the pyrogram) or insufficient
DNA (producing a weak signal).
SNP calls obtained by pyrosequencing were adjusted using
standard curve equations derived from pyrosequencing of
mixtures of control DNA strains with known proportions
for each allele. To account for machine error, the lower
cutoff for inclusion of minor alleles in a mixed infec-
tion was set at 10%. pfcrt K76T and pfmdr1 N86Y could
not be absolutely quantified using pyrosequencing so a
standard curve could not be applied. The minor allele fre-
quency cutoff for these two codons was set at 20% to ac-
count for both machine error and lack of adjustment by
standard curves.
Isolates were considered to be ‘pure’ mutants if only
the resistance-conferring codon was observed, and
‘mixed’ if both the wild-type and mutant allele were
detected. Similarly, haplotypes (combinations of poly-
morphisms) were considered ‘pure’ mutants if wild-type
alleles were not detected in any of the SNP positions,
and mixed if both wild-type and mutant alleles were
detected in at least one SNP position.
pfmdr1 copy number variation
pfmdr1 copy number was assessed by TaqMan real-time
PCR (ABI sequence detector 7700; Applied Biosystems,
Warrington, UK) using previously described primers,
probes, and reaction conditions [33]. Every qPCR run
contained genomic DNA extracted from P. falciparum
strains of 3D7, Dd2 and K1 with pfmdr1 copy numbers,
of 1, 2, and 3 respectively. Each sample in this assay was
run in triplicate. Assays were repeated if one of the fol-
lowing three results was obtained: ΔΔCt spread > 1.5; Ctvalues > 35; or copy number estimates between 1.3 and
1.6 [33].Microsatellite genotyping
Six microsatellites, located 2.8, 4.3, 10.8, and 29.3 kb up-
stream of pfcrt and 0.6 and 10.4 downstream of pfcrt on
chromosome 7, were used for genotyping. These
microsatellites were amplified using heminested PCR
and fluorescently labeled primers [44]. Specifics of PCR
reactions, thermal cycling conditions, and fragment size
calling were carried out as described by Laufer et al.
[45]. In addition to samples collected in this study, four
P. falciparum DNA samples collected between 2005 and
2007 in a previous study in Pakistan [15] and four col-
lected in Dagua Province in Papua New Guinea in 2010
were genotyped at all six microsatellite loci to assess
shared ancestry of the pfcrt locus.Results
A total of 801 microscopy-positive samples was collected
from 14 sites. Of these isolates, 128 samples were identi-
fied by PCR as P. falciparum and an additional 43 sam-
ples contained both P. falciparum and P. vivax
infections (Table 1) for a total of 171 samples containing
P. falciparum. Sixty three percent (108 samples) were
collected from male subjects and 37% (63 samples) were
collected from females. Subject age ranged from three
months to 75 years, with a median of 24 years.
Pyrosequencing of pfdhfr and pfdhps genes harbouring
mutations conferring drug resistance was carried out in
171 PCR-positive P. falciparum isolates. The pfdhfr
triple mutant N51I + C59R + S108N was detected in 7
samples, all carrying a mixture of wild-type and mutant
alleles (Table 2). The pfdhfr double mutant C59R + S108N
was found in 148 samples (87%) (Table 2). The pfdhps
mutant codon A437G was observed in 61 samples
(51.5%), with few mixed infections. pfdhps K540E was
found in six samples, and mixed K/E infections were
found in 131 samples (77%). pfdhps A581G was observed
in five samples while 66 samples (39%) had the mixed
A/G genotype. pfdhfr/pfdhps C59R + S108N + A437G
was found in 88 isolates (51%).
The distribution of common pfdhfr and pfdhps haplo-
types (combinations of polymorphisms) by region is
shown in Table 3. Prevalence of pfdhfr double mutant
C59R + S108N ranged from 72% in Punjab (in 31 of 43
samples) to 95% in Khyber Pakhtunkhwa (in 87 of 91
samples). pfdhfr C59R + S108N + pfdhps A437G was
present in 44-58% of samples collected in Punjab, Khyber
Pakhtunkhwa, and Balochistan (sample sizes of 43, 91,
and 33, respectively). Only two P. falciparum samples
each was collected from Islamabad and Sindh, and all four
carried pfdhfr C59R + S108N + pfdhps A437G.
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for pfcrt. DNA pyrosequencing of the secondary PCR
products from these samples confirmed that all of the
amplified samples carried codon K76T (nucleotide se-
quence ACA). All samples were of the SVMNT haplo-
type for pfcrt 72–76 (Table 2).
Pfmdr1 N86Y pure mutants were identified in six (4%)
of the tested isolates, 28 (16%) were identified as mixed
N/Y infections (Table 2). Forty-three (25%) isolatesTable 2 Number (N) and prevalence (%) of pure/mixed pfcrt,
resistance to chloroquine and sulphadoxine-pyrimethamine i







pfdhfr pfdhfr triple (N51I + C59R + S108N)
pfdhfr double (N51I + S108N)
pfdhfr double (C59R + S108N)




pfdhfr + pfdhps pfdhfr + pfdhps (C59R + S108N + A4carried the mixed Y/F codon at position Y184F of the
pfmdr1 gene and the remaining samples carried the
wild-type Y codon. One hundred and sixty-five (96%)
isolates carried the mixed N/D polymorphism at pos-
ition N1042D. All samples were wild-type for codons
S1034C and D1246Y. Real time PCR to determine copy
number variation in pfmdr1 gene revealed that all iso-
lates harboured a single copy of the pfmdr1 gene.
All six microsatellite loci amplified successfully in 160
of 171 P.falciparum samples. Three isolates were mixed-
strain infections with multiple alleles at each locus and
were excluded from further analysis. Three haplotypes
were observed in the remaining sample set of 157: the
predominant haplotype, found in 137 samples, and two
haplotypes in 12 and eight samples, respectively, each
differing from the predominant haplotype at one micro-
satellite locus (Table 4). These pfcrt flanking microsatel-
lite haplotypes were identical or nearly identical
(differing in 1 locus) to those found in isolates with the
SVMNT haplotype from Pakistan [15] and Papua New
Guinea (Table 4).
Discussion
In this study, polymorphisms in the pfdhfr, pfdhps, pfcrt
and pfmdr1 genes were investigated in P. falciparum
samples collected throughout Pakistan to determine the
current extent of resistance to chloroquine and
antifolates, both of which are still used as part of first-
line treatment of malaria in Pakistan.
The complete saturation of pfcrt K76T in all parts of
the country indicates that chloroquine-resistant P. fal-
ciparum is fixed in Pakistan. These findings corroboratepfmdr1, pfdhfr and pfdhps mutant alleles conferring
n Plasmodium falciparum isolates from Pakistan
Pure Mixed
N (%) N (%)
171 (100) 0 (0)
6 (4) 28 (16)
0 (0) 43 (25)
0 (0) 0 (0)
0 (0) 165 (96)
0 (0) 0 (0)
0 (0) 7 (4)
11 (6) 3 (2)
148 (87) 9 (5)
4 (2) 77 (45)
103 (60) 3 (2)
6 (4) 131 (77)
5 (3) 66 (39)
37G) 88 (51) 6 (4)
Table 3 Number and prevalence of SP resistance-associated haplotypes in pfdhfr and pfdhps in Pakistan, by province
Number and prevalence (%) of pfdhfr, pfdhps, and pfdhfr + pfdhps alleles
pfdhfr N51I + C59R +
S108N




pfdhfr C59R + S108N + pfdhps
A437G
n Mixed* Pure** Pure Mixed Pure Mixed Pure Mixed
Balochistan 33 4 (12) 1 (3) 26 (79) 1 (3) 2 (6) 16 (49) 19 (58) 0
KPK*** 91 0 2 (2) 87 (95) 1 (1) 1 (1) 32 (35) 46 (51) 1 (1)
Islamabad 2 0 0 2 (100) 0 0 2 (100) 2 (1) 0
Punjab 43 3 (7) 8 (19) 31 (72) 1 (2) 1 (2) 25 (58) 19 (44) 5 (12)
Sindh 2 0 0 2 (100) 0 0 2 (100) 2 (100) 0
Total 171 7 (4) 11 (6) 148 (87) 3 (2) 4 (2) 77 (45) 88 (52) 6 (4)
*Mixed pfdhfr N51I + S108N not detected.
**Pure pfdhfr triple mutant not detected.
***KPK: Khyber Pakhtunkhwa.
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chloroquine resistance [15,37] and clinical studies
reporting high treatment failure of chloroquine [2,7,8].
Chloroquine resistance has also been documented in
several neighbouring countries, including Iran, India,
China and Afghanistan [46-50]. Although chloroquine is
recommended for P. vivax infections only, P. falciparum
infections are often exposed to this treatment as well.
Presumptive diagnosis based on clinical grounds, im-
proper diagnosis, lack of diagnostic facilities, and empir-
ical treatment are common practices in resource-limited
countries such as Pakistan [51,52], and these factorsTable 4 Microsatellite haplotypes of Plasmodium falciparum p
chromosome 7
Country of origin Number or strain pfcrt haplotype




Papua New Guinea 2 SVMNT
2 SVMNT
Papua New Guinea D10 CVMNK
Thailand K1 CVIET







Sierra Leone D6 CVMNK
*Numbers indicate distance in kilobases upstream (−) and downstream (+) of the p
**Reference [14].likely result in the continued mistreatment of P. falcip-
arum infections with chloroquine. Such ineffective treat-
ment of chloroquine-resistant P. falciparum with
chloroquine can lead to increased morbidity and mortal-
ity if infections do not respond to the drug. Use of
chloroquine to treat P. falciparum has also been postu-
lated as contributing to the rapid growth of falciparum
malaria in Pakistan [2], as infections may not clear and
continue to circulate in the population unchecked.
Typing of microsatellites surrounding the pfcrt locus
indicates that a selective sweep of chloroquine-resistant
P. falciparum occurred in Pakistan, and that thearasites in the region flanking the pfcrt locus on
Microsatellites flanking pfcrt locus*
−29 −11 −4 −3 +1 +10
147 168 230 178 151 203
- - - 182 - -
- - - - - 197
- - - - - -
- - - - - -
149 - - - - -
- 170 - 166 - 193
- - 228 - 149 200
- 170 - 166 149 193
- 176 228 - 149 200
- 176 228 - 149 200
- 176 228 - 149 200
149 180 - 180 149 -
149 174 - - 157 200
149 182 - 184 147 193
145 186 232 186 149 200
fcrt locus.
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sites in Papua New Guinea. Previous studies have shown
that the SVMNT allele of the pfcrt locus appears to have
swept through Papua New Guinea [14], multiple parts of
India [16,46] and a small number of sites Pakistan [15].
Taken together with the findings in this study, these
results suggest that the spread of SVMNT may have
been a single sweep event through a large region
encompassing parts of the South Pacific and South Asia.
The possibility that such a large sweep could occur again
in the context of artemisinin resistance in this region
should be carefully considered.
The current first-line treatment for confirmed P. fal-
ciparum malaria in Pakistan is artesunate + SP. The
pfdhfr C59R + S108N double mutant was the most fre-
quent pyrimethamine-resistant haplotype found, as has
been shown in previous studies in Pakistan [1,37], India
[47,48], Iran [38,49], and Sri Lanka [50]. The majority of
samples also carried a mutation at position A437G and a
number of samples harboured mixed infections at highly
resistant codons K540E and A581G in the pfdhps gene.
Although the clinically significant pfdhfr triple mutation
was rare (and present only in mixed wild-type/mutant
infections) and pfdhfr/pfdhps quintuple mutants were
not detected, the presence of multilocus resistance hap-
lotypes and the presence of highly resistant sulphadoxine
alleles indicate that clinically relevant SP resistance
could arise or be already present. A recent clinical trial
in India reported artesunate + SP efficacy dipping to near
the WHO-established efficacy threshold of 90%, likely
attributable to the presence of multiple pfdhfr and
pfdhps mutations [53].
All samples harboured a single copy of the pfmdr1
gene, suggesting that artesunate, lumefantrine, and mef-
loquine are likely to have high efficacy in Pakistan, and
that the latter two could be considered as alternate ACT
partner drugs if the prevalence of SP resistance markers
rises. Presence of point mutations at position N86Y,
Y184F and N1042D of pfmdr1 indicate that continued
molecular monitoring of this gene may provide inform-
ative insights on its association with artemisinin and
partner drugs in this region.Conclusions
The fixation of chloroquine resistance marker pfcrt
K76T in Pakistan suggests that, in regions with known
high levels of P. falciparum, improved species diagnosis
and appropriate treatment with ACT are critical to en-
sure that malaria patients receive effective care. The
presence of multiple resistance alleles in pfdhfr and
pfdhps demonstrates the utility of molecular surveillance
to monitor the efficacy of artesunate + SP in Pakistan.
Based on these findings, molecular and therapeuticefficacy studies to assess the continued efficacy of
artesunate + SP are warranted.
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